{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:38:54Z","timestamp":1740166734982,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T00:00:00Z","timestamp":1594339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T00:00:00Z","timestamp":1594339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Asturpharma S.A. Consejer\u00eda de Educaci\u00f3n y Cultura del Principado de Asturias Banco de Santander-Universidad de Oviedo Oviedo"},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI151970"],"award-info":[{"award-number":["AI151970"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Antibiot"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1038\/s41429-020-0346-x","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T08:04:00Z","timestamp":1594368240000},"page":"868-872","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Spiropiperidyl rifabutins: expanded in vitro testing against ESKAPE pathogens and select bacterial biofilms"],"prefix":"10.1038","volume":"73","author":[{"given":"Mar\u0131a-Paz","family":"Cabal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0213-4726","authenticated-orcid":false,"given":"Timothy E.","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Turos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana-Bel\u00e9n","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessie L.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bridget G.","family":"Budny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey N.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,10]]},"reference":[{"key":"346_CR1","first-page":"146","volume":"14","author":"P Sensi","year":"1959","unstructured":"Sensi P, Margalith P, Timbal M. Rifomycin, a new antibiotic; preliminary report. Farmaco Ed Sci. 1959;14:146.","journal-title":"Farmaco Ed Sci."},{"key":"346_CR2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1146\/annurev.mi.26.100172.001215","volume":"26","author":"S Riva","year":"1972","unstructured":"Riva S, Silvestri LG. Rifamycins: a general view. Annu Rev Microbiol. 1972;26:199.","journal-title":"Annu Rev Microbiol."},{"key":"346_CR3","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.2174\/1381612043383287","volume":"10","author":"N Lounis","year":"2004","unstructured":"Lounis N, Rosceigno G. In vitro and in vivo activities of new rifamycin derivatives against mycobacterial infections. Curr Pharm Des. 2004;10:3229.","journal-title":"Curr Pharm Des."},{"key":"346_CR4","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1021\/cr030112j","volume":"105","author":"HG Floss","year":"2005","unstructured":"Floss HG, Yu TW. Rifamycin-mode of action, resistance, and biosynthesis. Chem Rev. 2005;105:621.","journal-title":"Chem Rev."},{"key":"346_CR5","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1002\/hlca.19730560716","volume":"56","author":"V Prelog","year":"1973","unstructured":"Prelog V, Oppolzer W. Ansamycins, a novel class of microbial metabolites. Helv Chim Acta. 1973;56:2279.","journal-title":"Helv Chim Acta"},{"key":"346_CR6","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1016\/S0040-4020(01)97558-1","volume":"30","author":"GG Gallo","year":"1974","unstructured":"Gallo GG, Martinelli E, Pagani V, Sensi P. The conformation of rifamycin S in solution by 1H NMR spectroscopy. Tetrahedron. 1974;30:3093.","journal-title":"Tetrahedron"},{"key":"346_CR7","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1159\/000220462","volume":"11","author":"N Maggi","year":"1966","unstructured":"Maggi N, Pasqualucci CR, Ballota R, Sensi P. Rifampicin: a new orally active rifamycin. Chemotherapy. 1966;11:285.","journal-title":"Chemotherapy"},{"doi-asserted-by":"crossref","unstructured":"Gallo GG, Radaelli P. Rifampin. In: Florey EK, editor. Analytical profiles of drug substances. New York: Academia Press; 1976. p. 467\u2013513.","key":"346_CR8","DOI":"10.1016\/S0099-5428(08)60328-7"},{"key":"346_CR9","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1073\/pnas.61.2.667","volume":"61","author":"W Wehrli","year":"1968","unstructured":"Wehrli W, Knusel F, Schmid K, Staehelin M. Interaction of rifamycin with bacterial RNA polymerase. Proc Natl Acad Sci USA. 1968;61:667\u201373.","journal-title":"Proc Natl Acad Sci USA."},{"key":"346_CR10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/0005-2787(69)90516-4","volume":"182","author":"W Wehrli","year":"1969","unstructured":"Wehrli W, Staehelin M. The rifamycins\u2014relation of chemical structure and action on RNA polymerase. Biochim Biophys Acta. 1969;182:24\u20139.","journal-title":"Biochim Biophys Acta."},{"key":"346_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1351\/pac197541010015","volume":"41","author":"P Sensi","year":"1975","unstructured":"Sensi P. Recent progress in the chemistry and biochemistry of rifamycins. Pure Appl Chem. 1975;41:15.","journal-title":"Pure Appl Chem."},{"key":"346_CR12","first-page":"699","volume":"6","author":"P Sensi","year":"1966","unstructured":"Sensi P, Maggi N, F\u00fcresz S, Maffii G. Chemical modifications and biological properties of rifamycins. Antimicrob Agents Chemother 1966;6:699\u2013714.","journal-title":"Antimicrob Agents Chemother"},{"unstructured":"Lancini G, Zanichelli W. Structure-activity relationships in rifamycins. In: Perlmann D, editor. Structure\u2013activity relationship among the semisynthetic antibiotics. New York: Academic Press; 1977. p. 531\u2013600.","key":"346_CR13"},{"unstructured":"Barluenga JM, Aznar Gomez F, Cabal Naves M-P, Garcia Delgado A-B, Valdes Gomez C. Preparation of spiropiperidyl rifamycin derivatives for therapeutic use in the treatment of mycobacterial infections. Spanish patent ES 2 246 155 A1, 2005; International patent PCT WO 2006\/027397 A1; European patent: EP 1 783 129 A1; US patent: US 2007\/0225266 A1.","key":"346_CR14"},{"key":"346_CR15","doi-asserted-by":"publisher","first-page":"5717","DOI":"10.1016\/j.bmcl.2006.08.090","volume":"16","author":"J Barluenga","year":"2006","unstructured":"Barluenga J, Aznar F, Garc\u00eda AB, Cabal M-P, Palacios JJ, Men\u00e9ndez MA. New rifabutin analogs: synthesis and biological activity against Mycobacterium tuberculosis. Bioorg Med Chem Lett. 2006;16:5717\u201322.","journal-title":"Bioorg Med Chem Lett."},{"key":"346_CR16","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/mrc.1545","volume":"43","author":"E Rubio","year":"2005","unstructured":"Rubio E, Merino I, Garc\u00eda A-B, Cabal M-P, Ribas C, Bayod-Jasanada M. NMR spectroscopic analysis of new spiro-piperidylrifamycins. Magn Reson Chem. 2005;43:269\u201382. Erratum: Magn Reson Chem. 2006;44:654.","journal-title":"Magn Reson Chem."},{"key":"346_CR17","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.1128\/AAC.00149-10","volume":"54","author":"A-B Garc\u00eda","year":"2010","unstructured":"Garc\u00eda A-B, Palacios JJ, Ru\u00edz M-J, Barluenga J, Aznar F, Cabal M-P, Garc\u00eda JM, D\u00edaz N. Strong in vitro activities of two new rifabutin analogs against multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2010;54:5363\u20135.","journal-title":"Antimicrob Agents Chemother."},{"unstructured":"M07-A10. Methods for dilution antimicrobial tests for bacteria that grow aerobically. Approved standard. 10th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2015.","key":"346_CR18"},{"key":"346_CR19","doi-asserted-by":"publisher","first-page":"e00059","DOI":"10.1128\/AAC.00059-17","volume":"61","author":"R Fleeman","year":"2017","unstructured":"Fleeman R, Van Horn KS, Barber MM, Burda WN, Flanigan DL, Manetsch R, Shaw LN. Characterizing the antimicrobial activity of N2,N4-disubstituted quinazoline-2,4-diamines toward multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2017;61:e00059\u201317.","journal-title":"Antimicrob Agents Chemother."},{"key":"346_CR20","doi-asserted-by":"publisher","first-page":"e00491","DOI":"10.1128\/genomeA.00491-13","volume":"1","author":"RK Carroll","year":"2013","unstructured":"Carroll RK, Burda WN, Roberts JC, Peak KK, Cannons AC, Shaw LN. Draft genome sequence of strain CBD-635, a methicillin-resistant Staphylococcus aureus USA100 isolate. Genome Announc. 2013;1:e00491\u201313.","journal-title":"Genome Announc"},{"key":"346_CR21","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1128\/MMBR.00013-14","volume":"78","author":"D Lebeaux","year":"2014","unstructured":"Lebeaux D, Ghigo J-M, Beloin C. Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics. Microbiol Mol Bio Rev. 2014;78:510\u201343.","journal-title":"Microbiol Mol Bio Rev."},{"key":"346_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7:42717.","journal-title":"Sci Rep."},{"key":"346_CR23","doi-asserted-by":"publisher","first-page":"a027011","DOI":"10.1101\/cshperspect.a027011","volume":"6","author":"DM Rothstein","year":"2016","unstructured":"Rothstein DM. Rifamycins, alone and in combination. Cold Spring Harb Perspect Med. 2016;6:a027011.","journal-title":"Cold Spring Harb Perspect Med."},{"key":"346_CR24","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1128\/AAC.00161-10","volume":"54","author":"C Darkoh","year":"2010","unstructured":"Darkoh C, Lichtenberger LM, Ajami N, Dial EJ, Jiang Z-D, DuPont HL. Bile acids improve the antimicrobial effect of rifaximin. Antimicrob Agents Chemother. 2010;54:3618\u201324.","journal-title":"Antimicrob Agents Chemother."},{"key":"346_CR25","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2165\/00003088-200140050-00002","volume":"40","author":"WJ Burman","year":"2001","unstructured":"Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet. 2001;40:327\u201341.","journal-title":"Clin Pharmacokinet"}],"container-title":["The Journal of Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41429-020-0346-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41429-020-0346-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41429-020-0346-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:34:16Z","timestamp":1684618456000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41429-020-0346-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,10]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["346"],"URL":"https:\/\/doi.org\/10.1038\/s41429-020-0346-x","relation":{},"ISSN":["0021-8820","1881-1469"],"issn-type":[{"type":"print","value":"0021-8820"},{"type":"electronic","value":"1881-1469"}],"subject":[],"published":{"date-parts":[[2020,7,10]]},"assertion":[{"value":"25 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}